Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment ...

A study led by researchers at Beth Israel Deaconess Medical Center (BIDMC) has demonstrated that mpox antibody levels ...

Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...

Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic ...

The research, recently published in Nature Communications, found that when the molecule WD34 binds with a protein produced by ...

Plasma is vital to the survival of many patients and serves as a lifeline. October serves as a reminder of that ...

Innovative treatments using TRIM21 have successfully targeted tau aggregates in Alzheimer’s, showing potential for broader ...

Glioblastoma is the most common and most aggressive primary brain tumour, with an average survival after diagnosis of less ...

BIDMC research shows people previously vaccinated against mpox in 2022 had declining antibody responses after six to 12 ...

A high density of tumor-associated macrophages (TAMs) is associated with poorer prognosis and survival in breast cancer patients. Recent studies have shown that lipid accumulation in TAMs can promote ...

This useful study by Gao et al identifies Hspa2 as a heterogeneous transcript in the early embryo and proposes a plausible mechanism showing interactions with Carm1. The authors propose that ...